V21A (p.Val21Ala) variant of SGCD (Delta-sarcoglycan)
V21A (p.Val21Ala) in SGCD (Delta-sarcoglycan) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.26 / 1. The record also includes structural context.
V21A (p.Val21Ala) variant details
- p.Val21Ala
- NCI-TCGA Cosmic COSV6190
- cosmic curated COSV61904
- TOPMed rs1768843296
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.255
- ESM-1b 0.00
- AlphaMissense 0.22
- UniProt: Variant assessed as somatic; moderate impact.
- Structural context available